Novavax (NVAX) Stock Still Looks Pricey As Sales Struggle To Support It

Novavax stock has delivered a steep decline of around 96% over the past five years, yet its current valuation checks and recent 12 month gain of 17.3% leave a more nuanced picture of what investors are paying for today.

• The share price decline of about 96% over five years suggests long term holders have absorbed heavy losses, so any current valuation case needs to be weighed against that track record.
• For a vaccine focused business like Novavax, expectations around future product uptake and funding can support the valuation, while uncertainty around sustained revenue and cash flow can limit how much investors are willing to pay.
• On Simply Wall St's broader checks, Novavax screens as a mixed proposition rather than clearly cheap or clearly expensive, with a value score of 4 out of 6. This suggests some measures look reasonable, while others lean rich.

For investors, the debate is whether the current price around US$8.21 already reflects Novavax's risks and potential, or still asks too much after such a large long term drawdown.

Find out why Novavax's 17.3% return over the last year is lagging behind its peers.

Does Novavax Look Pricey on Sales?

A price to sales lens suits Novavax because revenue is more established than consistent profits at this stage. On this measure, Novavax trades at about 2.3x P/S, using the current share price and last reported revenue.

That 2.3x level sits well below the wider Biotechs industry average of roughly 11.3x and also below the peer average of 39.3x. However, a more tailored fair multiple that factors in Novavax's size, risks and financial profile sits lower still at around 1.5x. The gap between the current 2.3x and this 1.5x fair ratio means the stock appears overvalued on a P/S basis, even if it looks inexpensive against many peers.

Overall, Novavax stock currently appears overvalued on its P/S multiple when set against the fair ratio implied by its own fundamentals.

See what the numbers say about this price — find out in our valuation breakdown.

The Novavax Narrative: What Would Justify Today's Price?

Simply Wall St's Narratives for Novavax pick up where this valuation puzzle leaves off by spelling out what kind of future path for the company's growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than today's price on the Community page. Each narrative links its number to a clear view of how Novavax's business, profitability and risks might evolve, giving you a reference point to revisit as new information comes through.

Community views on Novavax sit far apart, with one camp leaning into licensing upside and the other focused on how fragile those streams could be.

Bull case: 40% undervalued

"Partnership with Sanofi has de-risked commercial execution for Nuvaxovid and opened doors for future milestone and royalty streams, particularly as Sanofi develops and commercializes COVID-influenza combination vaccines, which could meaningfully boost Novavax's recurring revenue and net margins..."

Read the full Bull Case to see why Novavax could be undervalued

Bear case: 17% overvalued

"Heavy historical dependence on a narrow product portfolio, primarily COVID-19 and flu vaccines, magnifies Novavax's vulnerability to rapid market saturation, declining demand post-pandemic, and competitive displacement, increasing the likelihood of sharp revenue contraction once near-term milestone payments and royalties subside..."

Read the full Bear Case to see why Novavax could be overvalued

Do you think there's more to the story for Novavax? Head over to our Community to see what others are saying!

The Bottom Line

For now, Novavax looks overvalued on its tailored P/S multiple, even though the broader checks paint a mixed picture rather than a clear bargain or clear bubble. That leaves the stock in a middle ground where the market appears to be paying up for potential that is not fully backed by current fundamentals. What matters most from here is whether Novavax can convert its partnerships and product pipeline into steadier, recurring revenue that justifies the premium implied by today’s sales multiple, or whether the market is still pricing in more than the business ultimately delivers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com